Get notified of page updates

Prevention

Observational study for people with family history of pancreas cancer or an inherited mutation linked to pancreatic cancer risk

Clinicaltrials.gov identifier:
NCT03568630

Study Contact Information:

For additional information, please contact: Suzanne Wessling, RN by phone: 402-559-1577 or by email: suzanne.wessling@unmc.edu or
Kelsey A Klute, MD by phone: 402-559-8500 or by email

PRINTER FRIENDLY PAGE

Blood Markers of Early Pancreas Cancer

Prevention

Observational study for people with family history of pancreas cancer or an inherited mutation linked to pancreatic cancer risk

Clinicaltrials.gov identifier:
NCT03568630

Study Contact Information:

For additional information, please contact: Suzanne Wessling, RN by phone: 402-559-1577 or by email: suzanne.wessling@unmc.edu or
Kelsey A Klute, MD by phone: 402-559-8500 or by email

PRINTER FRIENDLY PAGE
Glossary on
off

About the Study

The purpose of this study is to try to find markers of early pancreatic cancer for individuals at higher-than-average risk, expedite the diagnosis in individuals with symptoms, and substantially improve an individual's chance of surviving the disease.

This Study is Open To:

Men and women age 19 years or older can be considered for enrollment in this study if they meet one of the following criteria:

  • Have new onset type 2 diabetes, or are considered high-risk pre-diabetes
  • Have pancreatic neoplasms (abnormal growths) or pancreatitis
  • Have family history of pancreatic cancer or have an increased risk due to an in any one of the following genes: , , , , , , , , , CKDN2a, p16, , , SMAD4, BMPR1A, , CFTR

This Study is NOT Open To:

  • Patients with a personal history of pancreatic cancer
  • Patients who are currently receiving treatment for a cancer diagnosis (excluding long-term hormonal therapy)
  • Patients who are pre-diabetic and taking metformin for 3 or more years

What the Study Involves

Each study participant will undergo blood tests that measure a blood sugar marker called Hemoglobin A1c as well as other markers. The blood samples are frozen until the end of the study and will be researched at that time. 

Participants may include people at high risk for pancreatic cancer due to the following: 

  • people with family history of pancreas cancer or an linked to pancreatic cancer risk, including the following: , , , CKDN2a, p16, , , SMAD4, BMPR1A, , CFTR or (, , , , ).
  • people with cystic pancreas lesions or chronic pancreatitis.
  • people with new-onset diabetes.   

Study participants will be followed for five years.

Study Contact Information:

For additional information, please contact: Suzanne Wessling, RN by phone: 402-559-1577 or by email: suzanne.wessling@unmc.edu or
Kelsey A Klute, MD by phone: 402-559-8500 or by email

Locations:

Nebraska

City: Omaha RECRUITING
Facility: Unversity of Nebraska Medical Center
Contact Info:
suzanne.wessling@unmc.edu 402-559-1577